Therapeutic Potential of Transcranial Focused Ultrasound for Rett Syndrome

Shih-Jen Tsai

Corresponding Author: Shih-Jen Tsai, e-mail: tsai610913@gmail.com

Source of support: Self financing

Rett syndrome (RTT) is a severe neurodevelopmental disorder occurring almost exclusively in females and is caused by loss-of-function mutations in the gene encoding methyl-CpG-binding protein 2 (MeCP2) in the majority of cases. MeCP2 is essential for the normal function of nerve cells, including neuronal development, maturation, and synaptic activity. RTT is characterized by normal early development followed by autistic-like features, slowed brain and head growth, gait abnormalities, seizures, breathing irregularities, and cognitive disabilities. Medical management in RTT remains supportive and symptomatic. Brain-derived neurotrophic factor (BDNF) has been implicated in the pathophysiology of RTT. Recent studies have shown a phenotypic reversal by increasing BDNF expression in a RTT mouse model. Thus, manipulation of BDNF expression/signaling in the brain could be therapeutic for this disease. Transcranial focused ultrasound for (tFUS) can noninvasively focally modulate human cortical function, stimulate neurogenesis, and increase BDNF in animal studies. Consequently, tFUS may be of therapeutic potential for Rett syndrome. Further evaluation of the therapeutic effects of tFUS in MeCP2 deficient animal models is needed before clinical trials can begin.

MeSH Keywords: Brain-Derived Neurotrophic Factor • Methyl-CpG-Binding Protein 2 • Neurogenesis • Rett Syndrome • Ultrasonography, Interventional

Full-text PDF: http://www.medscimonit.com/abstract/index/idArt/898041
Background

Rett syndrome (RTT) is a neurodevelopmental disorder that affects female children almost exclusively. RTT is the leading cause of severe intellectual disability in females, and is estimated to affect one in every 10,000 to 15,000 live female births in all ethnic groups worldwide. After 6 to 18 months of apparently normal early growth, RTT patients show global deceleration of psychomotor development and subsequent loss of acquired cognitive and motor skills. Children with RTT often exhibit autistic-like behaviours in the early stages and have slowed brain and head growth, problems with walking, seizures, and breathing irregularities [1,2]. The course of RTT varies from child to child, and children with RTT who survive into adulthood have severe mental retardation and require intensive support [3].

Nearly all RTT cases are caused by a mutation in the gene encoding the transcriptional regulator methyl-CpG-binding protein 2 (MeCP2), located on the X chromosome [4]. The MeCP2 protein is present in cells throughout the body, although it is particularly abundant in brain cells. Initially, MeCP2 was recognized as a transcriptional repressor/activator and, recently, it was also found to be involved in gene regulation at the post-transcriptional level [5–7]. Many of the genes that are known to be regulated by the MeCP2 protein are critical for the development and maturation of brain. Although mutations in the MECP2 gene have been found to cause RTT, the specific functions of MeCP2 that are impaired by mutations and are responsible for RTT symptomatology remain unclear [8].

To date, no successful curative treatment has been established for RTT; treatment for the disorder is symptomatic. Medication may be needed for breathing irregularities, and anticonvulsant drugs may be needed to control seizures [8]. Therapy programs for RTT patients should include the use of assistive technology and rehabilitation interventions to reverse physical impairments [9].

In recent years, some preliminary trials of theoretically potential agents have been proposed [10]. For example, the pleiotropic growth factor insulin-like growth factor-1 (IGF-1) has been suggested as a therapeutic treatment for RTT patients. IGF-1 crosses the blood-brain barrier (BBB) and stimulates proliferation of neural progenitors, neuronal survival, neurite outgrowth, and synapse formation [11]. A recent study demonstrated that systemic treatment of MeCP2 mutant mice with an active tripeptide fragment of IGF-1 extended the life span of the mice, improved locomotor functions, ameliorated breathing patterns, and reduced irregularities in heart rates [12].

Here, I propose that transcranial focused ultrasound (tFUS), a novel noninvasive brain stimulation technique, could be a potential treatment for RTT by improving several key features of RTT.

Medical Hypothesis

Brain-derived neurotrophic factor (BDNF) deregulation in Rett syndrome

BDNF is a member of the neurotrophin family of growth factors that have essential roles in neuronal survival and differentiation, and is a strong modulator of synaptic transmission and plasticity in the brain. In 2003, Bdnf gene was first identified as a possible neuronal target gene for MeCP2 [13]. Later it was found that BDNF protein levels in the whole-brain lysate in MeCP2 knockout mice were decreased to about 70% of the wild-type level [14]. Lower BDNF mRNA levels were also found in autopsy brain samples from RTT subjects, which is similar to that found in MeCP2 mutant mice [15,16]. Animal study demonstrated that deletion of Bdnf in MeCP2 mutants caused an earlier onset of RTT-like symptoms, whereas increased brain BDNF expression in the MeCP2 mutant extended the lifespan, rescued a locomotor defect, and reversed an electrophysiological deficit [14]. These findings suggested that RTT pathogenesis may be partially mediated through BDNF signalling, and therefore improving BDNF expression and/or signaling in brain could be therapeutic for this disease [14]. Since the administration of BDNF is not a useful clinical approach due to its low BBB penetration, medications that can increase endogenous BDNF expression or its downstream signaling pathways are more practical for the treatment of RTT [8,10].

Irregular breathing is one of the most typical symptoms of RTT. Common issues are hyperventilation, apnea, breath holding, and air swallowing that occurs generally while awake. Evidence from previous studies suggested BDNF signaling plays an important role in the respiratory pathophysiology of RTT [17,18]. A recent study using 7,8-dihydroxyflavone (7,8-DHF), a small molecule reported to activate the high affinity BDNF receptor (TrkB) in the brain, demonstrated delayed body weight loss, increased neuronal nuclei size, and improvement in breathing pattern irregularities in MeCP2 mutant mice [19]. Another study by Schmid et al. [20] reported LM22A-4, a small molecule TrkB agonist, could increase TrkB activation and improve respiratory function in heterozygous female MeCP2 mutant mice.

Transcranial focused ultrasound

Ultrasound, also called sonography, is safe and creates images of the inside of the body using sound waves. Most ultrasounds are done using a transducer on the surface of the body. Advancements in ultrasound technology may permit physicians to get a better diagnostic image by inserting a special
transducer into one of the body’s natural openings [21–23]. The new ultrasound modality tFUS delivers highly focused acoustic energy to a small region of the brain in a noninvasive manner. Recently tFUS has been investigated as a new mode of noninvasive brain stimulation, which offers high spatial resolution and depth control. In addition, tFUS has been used for targeted drug delivery by reversible BBB disruption [24]. Recently, tFUS, with its ability to deliver highly focused acoustic energy to a small region of the brain in a noninvasive manner, is gaining attention as a new mode of brain stimulation [25,26]. Some preliminary studies suggest that tFUS could be used for the treatment of patients with neuropathic pain, essential tremor, Parkinson’s disease, Alzheimer’s disease, or major depression [26–29]. It could be a potential strategy for the treatment of RTT for several reasons. Firstly, tFUS at low intensities has demonstrated the potential to increase growth factors, including BDNF [30]. A previous study demonstrated that MeCP2 mutants could be rescued by application of exogenous BDNF [31]. Furthermore, Bdnf overexpression in embryonic day-18 hippocampal neurons prevents dendritic atrophy caused by MeCP2 mutations [32]. These findings suggest that the brain BDNF level is decreased in RTT, and therapeutic approaches aimed at increasing BDNF levels may be able to counteract the effects of mutant MeCP2. Recently, Tufail et al. [30] demonstrated that hippocampal BDNF protein levels were increased following transcranial stimulation by tFUS in mice. Similarly, Yang et al. [33] reported that low-intensity pulsed ultrasound stimulation in rat brain astrocytes is capable of increasing neurotrophic protein levels, including BDNF.

Secondly, hippocampal neurogenesis is central to learning and memory. A study using a human neuroblastoma cell line carrying a partially silenced MECP2 gene found that MECP2 inactivation affected the cell fate of neural progenitors and/or neuronal differentiation and maintenance [34]. In a recent study, Hao et al. [35] demonstrated that fornical deep brain stimulation can restore in vivo hippocampal long-term potentiation and hippocampal neurogenesis in RTT mice. In adult mice, tFUS significantly increased the number of proliferating cells and newborn neurons in the hippocampus [36]. This provides further evidence that tFUS can stimulate hippocampal neurogenesis, a process involved in learning and memory and affected in RTT.

References:

1. Liyange VR, Rastegar M. Rett syndrome and MeCP2. Neuro molecular Med, 2014; 16(2): 231–64
2. Segawa M, Nomura Y: Rett syndrome. Curr Opin Neurol, 2005; 18(2): 97–104
3. Freilinger M, Bebbington A, Lator I et al: Survival with Rett syndrome: Comparing Rett’s original sample with data from the Australian Rett Syndrome Database. Dev Med Child Neurol, 2010; 52(10): 962–65
4. Amir RE, Van den Veyver IB, Wan M et al: Rett syndrome is caused by mutations in X-linked MECPP2, encoding methyl-CpG-binding protein 2. Nat Genet, 1999; 23(2): 185–88

Evaluation of the Hypothesis

The use of tFUS in RTT deserves a thorough examination. I present several recommendations for applying this hypothesis of RTT treatment with tFUS. Firstly, the discovery of the main RTT gene, MECP2, enabling several mouse models of RTT based on MeCP2 dysfunction, and allowed testing of the potential therapeutic effect of tFUS in RTT subjects [37,38]. Furthermore, induced pluripotent stem cells (iPSCs) reprogrammed from skin fibroblasts of RTT individuals have been successfully differentiated into neurons [39]. RTT patient iPSC-derived neurons have shown changes in soma size, information encoding properties, and synaptic connectivity that are defective in RTT [39]. The therapeutic potential of tFUS in RTT subjects could thus be tested in this iPSC model of RTT. Second, any promising results in animal or iPSC model studies, suggest the need for further double-blind, placebo-controlled randomized studies to confirm that tFUS has therapeutic effects in RTT patients. The beneficial effects of tFUS in the brain seem to be related to timing and dose. The optimal tFUS parameters for RTT treatment await further exploration. Finally, all safety concerns should be evaluated in preclinical and clinical studies during tFUS treatment of RTT patients.

Conclusions

Currently, tFUS, a noninvasive brain stimulation, is being used experimentally to enhance brain plasticity and recovery of function through increasing BDNF levels and neurogenesis. The tFUS methodology may offer protection to the neurological systems and improve the respiratory and cognitive function of patients with RTT. Obviously, further experimental studies and clinical trials are needed in order to confirm the therapeutic potential of tFUS in RTT patients.

Declaration of interest

None.
8. Chapleau CA, Lane J, Pozzo-Miller L, Percy AK: Evaluation of current pharmacological treatment options in the management of Rett syndrome. From the present to future therapeutic alternatives. Curr Clin Pharmacol, 2013; 8(4): 358–69

9. Lotan M: Assistive technology and supplementary treatment for individuals with Rett syndrome. ScientificWorldJournal, 2007; 7: 903–48

10. Katz DM, Bird A, Coenraads M et al: Rett syndrome: Crossing the threshold to clinical translation. Trends Neurosci, 2016; 39(2): 100–13

11. D’Ercole AJ, Ye P, Calikoglu AS, Gutierrez-Ospina G: The role of the insulin-like growth factors in the central nervous system. Mol Neurobiol, 1996; 13(3): 227–55

12. Tropea D, Giacometti E, Wilson NR et al: Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice. Proc Natl Acad Sci USA, 2009; 106(6): 2029–34

13. Chen WG, Chang Q, Lin Y et al: Derepression of BDNF transcription involves calcium-dependent phosphorylation of MeCP2. Science, 2003; 302(5646): 885–89

14. Chang Q, Khare G, Dani V et al: The disease progression of MeCP2 mutant mice is affected by the level of BDNF expression. Neuron, 2006; 49(3): 341–48

15. Abuhazira L, Makedonski K, Kaufman Y et al: MeCP2 deficiency in the brain decreases BDNF levels by REST/CoREST-mediated repression and increases TrkB production. Epigenetics, 2007; 2(4): 214–22

16. Deng V, Matagne V, Banine F et al: FXYD1 is an MeCP2 target gene overexpressed in the brains of Rett syndrome patients and MeCP2-null mice. Hum Mol Genet, 2007; 16(6): 640–50

17. Lisy DT, Wu WW, Bissonnette JM: Autonomic dysfunction with mutations in the gene that encodes methyl-CpG-binding protein 2: Insights into Rett syndrome. Auton Neurosci, 2011; 161(1–2): 55–62

18. Ogier M, Kron M, Katz DM: Neurotrophic factors in development and regulation of respiratory control. Compr Physiol, 2013; 3(3): 1125–34

19. Johnson RA, Lam M, Punzo AM et al: 7,8-dihydroxyflavone exhibits therapeutic efficacy in a mouse model of Rett syndrome. J Appl Physiol (1985), 2012; 112(5): 704–10

20. Schmid DA, Yang T, Ogier M et al: A TrkB small molecule partial agonist rescues TrkB phosphorylation deficits and improves respiratory function in a mouse model of Rett syndrome. J Neurosci, 2012; 32(5): 1803–10

21. Torres-Ayala SC, Maldonado J, Bolton JS, Bhalla S: Coronary computed tomography angiography of spontaneous coronary artery dissection: A case report and review of the literature. Am J Case Rep, 2015; 16: 130–35

22. Seabra LF, Ribeiro HB, de Barros ESPG et al: Left main ostial compression in a patient with pulmonary hypertension: Dynamic findings by IVUS. Am J Case Rep, 2015; 16: 899–903

23. Siegel RJ, Luo H: Ultrasound thrombolysis. Ultrasonomics, 2008; 48(4): 312–20

24. Yang FY, Lin YS, Kang KH, Chao TK: Reversible blood-brain barrier disruption by repeated transcranial focused ultrasound allows enhanced extravasation. J Control Release, 2011; 150(1): 111–16

25. Jolesz FA, McDonnell N: Magnetic resonance-guided focused ultrasound: A new technology for clinical neurosciences. Neurol Clin, 2014; 32(1): 253–69

26. Bauer R, Martin E, Haegele-Link S et al: Noninvasive functional neurosurgery using transcranial MR imaging-guided focused ultrasound. Parkinsonism Relat Disord, 2014; 20(Suppl.1): S197–99

27. Wintermark M, Huss DS, Shah BB et al: Thalamic connectivity in patients with essential tremor treated with MR imaging-guided focused ultrasound: In vivo fiber tracking by using diffusion-tensor MR Imaging. Radiology, 2014; 272(1): 202–9

28. Tsai SI: Transcranial focused ultrasound as a possible treatment for major depression. Med Hypotheses, 2015; 84(4): 831–83

29. Lin WT, Chen RC, Lu WW et al: Protective effects of low-intensity pulsed ultrasound on aluminum-induced cerebral damage in Alzheimer’s disease rat model. Sci Rep, 2015; 5: 9671

30. Tufail Y, Matyszuhov A, Baldwin N et al: Transcranial pulsed ultrasound stimulates intact brain circuits. Neurol, 2010; 66(5): 681–94

31. Kline DD, Ogier M, Kunze DL, Katz DM: Exogenous brain-derived neurotrophic factor rescues synaptic dysfunction in MeCP2-null mice. J Neurosci, 2010; 30(15): 5303–10

32. Lamoreiro JL, Chapleau CA, Kudo S et al: Bdnf overexpression in hippocampal neurons prevents dendritic atrophy caused by Rett-associated MeCP2 mutations. Neurobiol Dis, 2009; 34(2): 199–211

33. Yang FY, Lu WW, Lin WT et al: Enhancement of neurotrophic factors in astrocyte for neuroprotective effects in brain disorders using low-intensity pulsed ultrasound stimulation. Brain Stimul, 2015; 8(3): 465–73

34. Squillaro T, Alessio N, Cippolino M et al: Reduced expression of MeCP2 affects cell commitment and maintenance in neurons by triggering senescence: New perspective for Rett syndrome. Mol Biol Cell, 2012, 23(8): 1435–45

35. Hao S, Tang B, Wu Z et al: Fornical deep brain stimulation rescues hippocampal memory in Rett syndrome mice. Nature, 2015; 526(7573): 340–34

36. Scarcelli T, Jorda JoF, O’Reilly MA et al: Stimulation of hippocampal neurogenesis by transcranial focused ultrasound and microbubbles in adult mice. Brain Stimul, 2014; 7(2): 304–7

37. Cafta G, Percy AK, Pozzo-Miller L: Experimental models of Rett syndrome based on MeCP2 dysfunction. Exp Biol Med (Maywood), 2011; 236(1): 3–19

38. Li W, Pozzo-Miller L: BDNF deregulation in Rett syndrome. Neuropharmacology, 2014; 76 Pt C: 737–46

39. Djuric U, Cheung AV, Zhang W et al: MeCP2e1 isoform mutation affects the form and function of neurons derived from Rett syndrome patient IPS cells. Neurobiol Dis, 2015; 76: 37–45